Combination therapy of a PARP inhibitor and a multifunctional molecule binding to tcr
Combining a TCRβV-binding agent with a PARP inhibitor enhances anti-tumor immune response by activating/co-inhibiting receptors, addressing the limitations of monotherapies and improving therapeutic outcomes.
WO2026112599A2PCT designated stage Publication Date: 2026-05-28MARENGO THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- MARENGO THERAPEUTICS INC
- Filing Date
- 2025-11-24
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Monotherapies using current cancer therapeutics, such as multifunctional molecules binding to TCR or PARP inhibitors, have limited therapeutic effects.
Method used
A combination therapy involving a first agent that binds to the TCR β variable (TCRβV) region and activates/co-inhibits a co-stimulatory/co-inhibitory receptor, and a second agent comprising a Poly-ADP ribose polymerase (PARP) inhibitor, to enhance anti-tumor immune response.
Benefits of technology
The combination therapy induces more activated and expanded T cells, reduces exhausted T cells, and increases cytotoxicity against tumor cells, resulting in improved therapeutic efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025056898_28052026_PF_FP_ABST
Abstract
Provided herein are methods of treating conditions or diseases in a subject using a combination of a PARP inhibitor and a molecule comprising an antigen binding domain that binds to a T cell receptor beta variable region (TCRβV) and a molecule that activates a co-stimulatory receptor or a molecule that inhibits a co-inhibitory receptor. Kits for use in practicing the methods are also provided.
Need to check novelty before this filing date? Find Prior Art